Redirecting an Anticancer to an Antibacterial Hit Against Methicillin-Resistant Staphylococcus aureus

Redirecting an Anticancer to an Antibacterial Hit Against Methicillin-Resistant Staphylococcus aureus

YM155 is a clinically evaluated anticancer with a fused naphthoquinone-imidazolium scaffold. In this study, we demonstrated that based on weak or cryptic antibacterial activity of YM155 against methicillin-resistant Staphylococcus aureus (MRSA) (MIC of 50 μg/ml), some congeneric compounds with short...

Full description

Bibliographic Details
Main Authors: Hye-Jeong Jang, In-Young Chung, Changjin Lim, Sungkyun Chung, Bi-o Kim, Eun Sook Kim, Seok-Ho Kim, You-Hee Cho
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-02-01
Series:Frontiers in Microbiology
Subjects:
MRSA
gram-positive
antibacterials
drug repurposing
drug redirecting
Online Access:https://www.frontiersin.org/article/10.3389/fmicb.2019.00350/full

Internet

https://www.frontiersin.org/article/10.3389/fmicb.2019.00350/full

Similar Items